Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Phenotypic And Molecular Characterization Of The Claudin-low Intrinsic Subtype Of Breast Cancer

A. Prat, J. Parker, O. Karginova, C. Fan, C. Livasy, J. Herschkowitz, X. He, C. Perou
Published 2010 · Medicine, Biology

Save to my Library
Download PDF
Analyze on Scholarcy
Share
IntroductionIn breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype.MethodsThe clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets. These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models.ResultsClaudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features. Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell.ConclusionsThese results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines.
This paper references
10.1093/JNCI/58.6.1795
Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines.
A. Hackett (1977)
10.1093/JNCI/92.7.564
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
M. Esteller (2000)
10.1038/nm.2000
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
E. Lim (2009)
Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
G Dontu (2003)
The R Project for Statistical Computing. [http://cran.r-project.org]
10.1158/0008-5472.CAN-08-2741
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
E. Charafe-Jauffret (2009)
University of North Carolina Microarray Database
LJ Van’tVeer
10.1186/1471-2164-8-258
EGFR associated expression profiles vary with breast tumor subtype
K. Hoadley (2007)
10.1186/bcr2142
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
J. Herschkowitz (2008)
10.1038/73432
Systematic variation in gene expression patterns in human cancer cell lines
D. T. Ross (2000)
10.1158/0008-5472.CAN-05-2853
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
F. Elstrodt (2006)
10.1111/J.1432-0436.1998.00201.X
Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast.
J. Stingl (1998)
10.1158/0008-5472.CAN-04-0107
Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer
M. Troester (2004)
10.1158/1078-0432.CCR-09-1532
Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
S. Park (2010)
10.1186/1471-2164-7-96
The molecular portraits of breast tumors are conserved across microarray platforms
Z. Hu (2006)
Breast Cancer Research Foundation and V Foundation for Cancer Research. AP is affiliated with the Internal Medicine doctoral program of the Autonomous University of Barcelona
10.1038/ng.127
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
I. Ben-Porath (2008)
10.1186/gb-2007-8-5-r76
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
J. Herschkowitz (2006)
10.1007/s10549-009-0619-3
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment
E. Resetkova (2009)
10.1186/bcr767
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
G. Arpino (2003)
10.1073/pnas.0711613105
BRCA1 regulates human mammary stem/progenitor cell fate
S. Liu (2008)
10.1073/pnas.0530291100
Prospective identification of tumorigenic breast cancer cells
M. Al-Hajj (2003)
10.1016/j.cell.2009.06.034
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
P. Gupta (2009)
10.1158/0008-5472.CAN-08-3441
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
B. Hennessy (2009)
10.1001/JAMA.295.21.2492
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
10.1186/1471-2164-7-115
Cell-type specific gene expression profiles of leukocytes in human peripheral blood
C. Palmer (2005)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1073/pnas.0905718106
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
C. Creighton (2009)
Genome Biol
H / E Samples From Claudin-Low (2007)
R68 http://breast-cancer-research.com/content
Prat (2010)
Cell-type-specific responses to chemotherapeutics in breast cancer
MA Troester (2004)
10.1158/1078-0432.CCR-06-1109
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
L. Carey (2007)
10.1038/nrc2620
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
K. Polyak (2009)
10.1371/journal.pone.0002888
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
A. Morel (2008)
10.1158/0008-5472.CAN-07-2017
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
D. Sarrió (2008)
10.1038/NM0797-730
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
D. Bonnet (1997)
10.1016/S1077-9108(08)79164-3
Refinement of breast cancer classification by molecular characterization of histological special types
G. Azabdaftari (2009)
10.1038/415530a
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
Bernards R: A gene-expression signature as a predictor of survival in breast cancer
M J Van De Vijver (2002)
10.1186/bcr1982
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
C. Fillmore (2007)
10.1007/BF02616069
Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma
R. K. Young (2007)
10.1038/sj.onc.1210014
BRCA1 dysfunction in sporadic basal-like breast cancer
N. Turner (2007)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
Cluster analysis and display of genome-wide expression patterns
C. Ferris (1999)
Department of Molecular & Cellular Biology
10.1198/016214508000000454
Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data
Yufeng Liu (2008)
10.1038/nm0809-842
Mammary development meets cancer genomics
A. Prat (2009)
10.1016/J.CCR.2006.10.008
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
R. Neve (2006)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat (2010)
Intrinsic Clustering as shown in Figure S1. Yellow array cluster: Claudin-low cluster as deened by SigClust
10.1016/j.stem.2008.05.018
Transcriptome analysis of the normal human mammary cell commitment and differentiation process.
Afshin Raouf (2008)
10.1158/0008-5472.CAN-3299-2
Lineage Infidelity of MDA-MB-435 Cells
Shankar Sellappan (2004)
10.1371/JOURNAL.PBIO.0030187
Determination of Stromal Signatures in Breast Carcinoma
R. West (2005)
[''R"--project for statistical computing].
R. Dessau (2008)
10.1038/nature08361
A luminal epithelial stem cell that is a cell of origin for prostate cancer
X. Wang (2009)
10.1016/j.stem.2007.08.014
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
C. Ginestier (2007)
Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
La Carey (2006)
10.1186/gb-2003-4-9-r60
DAVID: Database for Annotation, Visualization, and Integrated Discovery
G. Dennis (2003)
10.1093/jnci/djn123
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
X-b Li (2008)
BRCA1 mutation analysis Prat et alR68 http://breast-cancer-research.com/content/12/5/R68 of 41 human breast cancer cell lines reveals three new deleterious mutants
F Elstrodt (2006)
10.1093/JNCI/90.15.1138
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
S. Lakhani (1998)
10.1200/JCO.2006.05.6861
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
K. Hess (2006)
10.1056/NEJMOA052933
Concordance among gene-expression-based predictors for breast cancer.
C. Fan (2006)
BRCA 1 dysfunction in sporadic basal - like breast cancer
Lakhani (2006)
10.1101/GAD.1061803
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.
G. Dontu (2003)
10.1038/labinvest.2008.31
The fibromatosis signature defines a robust stromal response in breast carcinoma
A. Beck (2008)
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
J. (2002)
10.1016/J.CCR.2007.01.013
Molecular definition of breast tumor heterogeneity.
M. Shipitsin (2007)
10.1016/j.cell.2008.03.027
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A Mani (2008)



This paper is referenced by
Hacia una medicina personalizada del cáncer de mama: importancia de la clasificación molecular del tumor
Ana Lluch Hernández (2011)
10.1016/B978-1-4377-0604-8.00020-5
Molecular Classification of Breast Carcinoma
Rohit Bhargava (2012)
PARITY, OBESITY AND BREAST CANCER SURVIVAL: DOES INTRINSIC SUBTYPE MODIFY OUTCOMES?
Xuezheng Sun (2015)
10.1007/978-3-319-56673-3_15
Pathology of Breast Cancer
Frédérique Pénault-Llorca (2018)
Analysis of the Level of Oxidative Phosphorylatin in Breast Cancer Cell Types
Bratislav M. Janjic (2012)
Role of MAF in bone metastasis
Anna Tarragó (2017)
MicroRNA-455-3 p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI 24
Zhishuang Li (2017)
Effect of miR-146 a-5 p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX 5
SI Chengshuai (2018)
10.3892/OL.2016.4134
S100A8/A9 is associated with estrogen receptor loss in breast cancer.
Y. Bao (2016)
10.18632/oncotarget.12895
TRPC1-STIM1 activation modulates transforming growth factor β-induced epithelial-to-mesenchymal transition
Anne Schaar (2016)
10.1158/1078-0432.CCR-12-2123
Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
H. Brauer (2012)
10.1007/978-94-007-3907-9_18
Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study
P. Vermeulen (2012)
10.1016/j.ajpath.2013.08.002
Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.
A. G. Rivenbark (2013)
10.1134/S002689331601009X
Role of PDLIM4 and c-Src in breast cancer progression
D. S. Kravchenko (2016)
Caracterização da expressão de microRNAs em carcinoma de mama triplo negativo
S. Paulo. (2014)
10.1016/j.cell.2014.09.051
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
M. Boelens (2014)
10.1002/path.4280
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
B. Lehmann (2014)
10.1371/journal.pone.0087878
Loss of WISP2/CCN5 in Estrogen-Dependent MCF7 Human Breast Cancer Cells Promotes a Stem-Like Cell Phenotype
N. Ferrand (2014)
10.1016/j.tem.2012.02.006
Elf5, hormones and cell fate
H. J. Lee (2012)
10.4137/BIC.S9455
Molecular Profiling for Breast Cancer: A Comprehensive Review
M. Kittaneh (2013)
10.1007/s10549-011-1619-7
Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
J. Harrell (2011)
IDENTIFICATION OF PROTEOMIC CLUSTERS RELATED TO THE BREAST CANCER PROGRESSION
F. Costantini (2011)
10.1101/023127
Cancer classification in the genomic era: five contemporary problems
Qingxuan Song (2015)
10.1007/978-1-4939-8859-4_9
The Role of Notch in Breast Cancer
J. Bloodworth (2018)
LMW-E MEDIATES MAMMARY TUMORIGENESIS BY DEREGULATING ACINAR MORPHOGENESIS & GENERATING CANCER STEM CELLS
Mylinh T Duong (2012)
10.1016/j.celrep.2015.03.050
The proteomic landscape of triple-negative breast cancer.
R. T. Lawrence (2015)
10.18632/ONCOSCIENCE.146
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
Vineesh Indira Chandran (2015)
10.3389/fonc.2019.01349
OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts
Zhongyi Yan (2019)
10.3390/cancers11091351
Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins
Nora Jung (2019)
10.1002/1878-0261.12017
Epithelial–mesenchymal transition in tumor metastasis
K. T. Yeung (2017)
10.1101/796573
Metabolomic profiling of mouse mammary tumor derived cell lines reveals targeted therapy options for cancer subtypes
Martin P. Ogrodzinski (2019)
10.1172/JCI130323
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
S. García-Recio (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar